03/23/2022
Anapharm Bioanalytics acquires a new high sensitivity equipment: SCIEX Triple Quad 6500+ system
Anapharm Bioanalytics’ small molecule division continues to expand its capabilities with the acquisition of a new LC-MS/MS equipment tailored for method development and validation of high sensitivity assays. The new instrument increases our capabilities for peptide chemistry as well as for orally inhaled drugs such as for example Glycopyrronium; Indacaterol, Fluticasone, Salmeterol, Budesonide, Tiotropium, etc. in biological fluids.
The Triple Quad 6500+ system features multi-component IonDrive Technology including the IonDrive High Energy Detector+ that delivers revolutionary sensitivity, speed, and performance for the most challenging methods.
MORE NEWS
Overcoming Matrix Effects in the Analysis of Lipophilic Compounds
At the 10th EBF Young Scientist Symposium, we highlighted the complexities of analysing Fucoxanthin derivatives and demonstrated how innovative approaches, such as 2D Chromatography, can overcome these obstacles.
Overcoming Analytical Challenges in Liraglutide & Semaglutide Analysis
The work presented at the 10th EBF Young Scientist Symposium highlights the analytical challenges of developing UPLC/MS/MS methodologies for the extraction and quantification of Liraglutide and Semaglutide in plasma, while also outlining the strategies employed to solve them.
Anapharm Bioanalytics Recognized as an Innovative SME
We are thrilled to announce that Anapharm Bioanalytics has recently been officially recognized as an Innovative SME (PYME Innovadora) by the Spanish Ministry of Science and Innovation.